Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors

Do-Youn Oh; Tae-Min Kim; Sae-Won Han; Dong-Yeop Shin; Yun Gyoo Lee; Keun-Wook Lee; Jee Hyun Kim; Tae-You Kim; In-Jin Jang; Jong-Seok Lee; Yung-Jue Bang

doi:10.4143/crt.2014.258

Articles

Page Path: HOME > Cancer Res Treat > Volume 48(1); 2016 > Article

Original Article Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors: Do-Youn Oh, MD, PhD^1,2, Tae-Min Kim, MD, PhD^1,2, Sae-Won Han, MD, PhD^1,2, Dong-Yeop Shin, MD^1,3, Yun Gyoo Lee, MD^1,4, Keun-Wook Lee, MD, PhD⁵, Jee Hyun Kim, MD, PhD⁵, Tae-You Kim, MD, PhD^1,2, In-Jin Jang, MD, PhD⁶, Jong-Seok Lee, MD, PhD⁵, Yung-Jue Bang, MD, PhD^1,2,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2016;48(1):28-36.
DOI: https://doi.org/10.4143/crt.2014.258
Published online: February 23, 2015

¹Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

²Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

³Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea

⁴Department of Internal Medicine, Kangbuk Samsung Medical Center, Seoul, Korea

⁵Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

⁶Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul, Korea

Correspondence: Yung-Jue Bang, MD, PhD Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea
Tel: 82-2-2072-2390 Fax: 82-2-762-9662 E-mail: bangyj@snu.ac.kr

• Received: September 12, 2014 • Accepted: November 14, 2014

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

11,873 Views
140 Download
22 Web of Science
22 Crossref
23 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
CKD-516 is a newly developed vascular disrupting agent. This phase I dose-escalation study of CKD-516 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors.
Materials and Methods
Patients received CKD-516 intravenously on D1 and D8 every 3 weeks, in a standard 3+3 design. Safety was evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events ver. 4.02 and response was assessed by Response Evaluation Criteria in Solid Tumor ver. 1.1.
Results
Twenty-three patients were treated with CKD-516 at seven dosing levels: 1 mg/m²/day (n=3), 2 mg/m²/day (n=3), 3.3 mg/m²/day (n=3), 5 mg/m²/day (n=3), 7 mg/m²/day (n=3), 9 mg/m²/day (n=6), and 12 mg/m²/day (n=2). Mean age was 54 and 56.5% of patients were male. Two dose-limiting toxicities, which were both grade 3 hypertension, were observed in two patients at 12 mg/m²/day. The MTD was determined as 12 mg/m²/day. Most common adverse events were gastrointestinal adverse events (diarrhea, 34.8% [30.4% grade 1/2, 13.0% grade 3]; nausea, 21.7% [all grade 1/2]; vomiting, 21.7% [all grade 1/2]), myalgia (17.4%, all grade 1/2), and abdominal pain (21.7% [21.7% grade 1/2, 4.3% grade 3]). The pharmacokinetic study showed the dose-linearity of all dosing levels. Among 23 patients, six patients (26.1%) showed stable disease. Median progression-free survival was 39 days (95% confidence interval, 37 to 41 days).
Conclusion
This study demonstrates feasibility of CKD-516, novel vascular disrupting agent, in patients with advanced solid tumor. MTD of CKD-516 was defined as 12 mg/m²/day on D1 and D8 every 3 weeks.
Key words: CKD-516, Vascular disrupting agent, Phase I clinical trial, Solid tumor

Introduction

Angiogenesis is an essential component of tumorigenesis, and it has been an important target for development of new anti-cancer drugs. Antiangiogenic approach has mainly focused on preventing neovascularization. In contrast, antivascular approach targets endothelial cells and pericytes of the already established tumor vasculature. The new class of tubulin-binding agents, named vascular disrupting agents (VDAs), has been developed to target microtubules, not only in cancer cells, but also in the endothelium of tumor vessels [1]. These VDAs work by acting on the β-subunit of endothelial tubulin, resulting in depolarization of microtubules and disorganization of actin and tubulin, which leads to a major change in endothelial cell shape, increased vascular permeability, increased interstitial pressure followed by inhibition of blood flow and vasoconstriction [2]. The result is a rapid decrease of blood flow into the tumor and necrosis. Several VDAs are under clinical development including ombrabulin, ZD6126, etc. [3-5].

CKD-516 is a newly developed VDA. Its active drug (S-516) has a potent cytotoxicity against several cancer cells, including a P-glycoprotein overexpressing cell line (HCT15). It induces cell cycle arrest at G2/M phase, and strong inhibition of tubulin polymerization. It has shown marked antitumor efficacy against both murine tumors (CT26 and 3LL) and human xenografts (HCT116 and HCT15) in mice [6,7]. CKD-516 also enhances the antitumor effect of cytotoxic chemotherapy when administered in combination [8,9].

These promising preclinical data led to this phase I, firstin-human study of CKD-516 in patients with advanced solid tumors. The primary objective was to determine the maximum-tolerated dose (MTD) of CKD-516 when administered intravenously on day 1 and day 8 every 3 weeks. Assessment of safety and the pharmacokinetics (PK) were also primary objectives. Secondary objectives included assessment of preliminary antitumor efficacy.

Materials and Methods

This was a phase I, first-in-human, dose-escalation study of CKD-516 in patients with advanced solid tumors conducted at Seoul National University Hospital and Seoul National University Bundang Hospital. This study was approved by the Institutional Review Boards of each hospital and was registered with the United States National Library of Medicine (ClinicalTrials.gov) as NCT01028859.

1. Patient eligibility criteria

The following inclusion criteria were used for patient selection: (1) histologically confirmed solid tumors refractory to standard therapy or for which there is no standard therapy; (2) age, 20 to 75 years; (3) Eastern Cooperative Oncology Group (ECOG) performance status (PS), ≤ 2; (4) life expectancy of longer than 12 weeks; (5) adequate organ function (adequate hematologic function) ≥ 1,500/μL, platelet count ≥ 100,000 cells/μL, hemoglobin ≥ 9.0 g/dL, serum creatinine ≤ 1.5×upper limit of normal (ULN), serum bilirubin ≤ 1.5×ULN, aspartate transaminase, alanine aminotransferase ≤ 3×ULN [5×UNL in case of liver metastasis]); and (6) normal range of prothrombin time, activated partial thromboplastin time. Written informed consent was obtained from all patients. The important exclusion criteria were (1) central nervous system metastasis; (2) prior chemotherapy, radiation therapy, or surgery within 4 weeks prior to enrolling in the study; (3) heart failure, angina pectoris, New York Heart Association (NYHA) class III, IV congestive heart failure within 6 months of study; (4) uncontrolled hypertension (systolic blood pressure > 150 mm Hg or diastolic blood pressure > 100 mm Hg despite anti-hypertensive medication); and (5) under anticoagulation.

2. Treatment

CKD-516 was administered as a 30-minute intravenous infusion on day 1 and day 8 every 3 weeks. The starting dose was 1 mg/m²/day, and dose was escalated using 3+3 design and modified Fibonacci method. In each cohort, if a patient was withdrawn for any reason other than dose limiting toxicity (DLT) before completion of the 21-day administration period, the patient was replaced by another patient. Response was evaluated every two cycles. However, whenever disease progression was suspected, the response evaluation was allowed at the investigator’s discretion. Patients in whom antitumor effect was assessed as stable disease (SD), partial response (PR), or complete response (CR) for overall response at the end of the second cycle of treatment were allowed to receive further treatment. Treatment was to be continued until the subject experienced disease progression or unacceptable toxicity, withdrew consent, or required treatment with another therapeutic modality.

3. Definition of dose limiting toxicity

DLT was defined as follows: (1) grade 4 neutropenia lasting for ≥ 7 days or with fever; (2) grade 3-4 thrombocytopenia lasting for ≥ 7 days, or with bleeding or required platelets transfusion; (3) grade 3 or 4 nausea/vomiting or diarrhea despite optimal use of antiemetic drugs or antidiarrheal drugs; (4) other grade 3 or 4 non-hematological toxicity (except alopecia and anorexia); and (5) delay of > 2 weeks in administration of the next cycle due to inadequate recovery from toxicity of the first cycle. DLT was evaluated during the first cycle of treatment. The lowest dose at which DLT was observed in no more than two out of six patients in the first cycle of treatment was judged to be the MTD.

4. PK study procedure

Blood was collected on day 1 before and at the end of infusion, 10 minutes, 20 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours after dosing. Urine was collected on day 1, 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after dosing. Plasma and urine concentrations of CKD-516 and its active metabolite S-516 were determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with mosapride as an internal standard. Briefly, 200 μL of plasma or urine, methyl tert-butyl ether 1.5 mL, and mosapride 50 μL at 10 ng/mL were mixed thoroughly and centrifuged at 5,000 g for 5 minutes. The organic layer was separated and evaporated; the residue was reconstituted with 100 μL of 80% methanol, diluted 2-fold with mobile phase, and injected into the LC-MS/MS system. Chromatographic separation was performed on a Luna C18 column (50×2.0 mm, i.d., 5 μm; Phenomenex, Torrance, CA) under the isocratic condition using 0.05% formic acid in 10 mM ammonium formate and acetonitrile (70:30, v/v). The multiple-reaction monitoring was based on m/z transition of 537 > 270 for CKD-516, 438 > 270 for S-516, and 422 > 198 for mosapride (IS). The calibration ranges were linear with a lower limit of quantification of 0.5 ng/mL for CKD-516 and 0.2 ng/mL for S-516 in both human plasma and urine. The inter-assay precision and accuracy of the quality control (QC) samples were less than 9.54% and from 91.1% to 107%, respectively. Each analytical batch had six QC samples of known value, i.e., two for low, intermediate, and high concentrations, respectively. The analytical results were accepted only if the concentrations of > four out of the six QC samples were determined within 15% of the known values.

5. Assessment of outcomes

Safety and tolerability were measured by adverse events (AEs), vital sign, body weight, electrocardiogram (ECG), and laboratory tests. Safety was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) ver. 4.02. PK parameters of CKD-516 and S-516 were calculated using the noncompartmental method with Phoenix WinNonlin 6.1 (Pharsight, Mountain View, CA). The pharmacokinetic linearity was assessed by linear regressions between dose and C_max or AUC_last and between log-transformed dose and log-transformed C_max or log-transformed AUC_last. Efficacy was measured using Response Evaluation Criteria in Solid Tumor (RECIST) ver. 1.1. Tumor responses were assessed after the first cycle or earlier in patients with suspected progression.

6. Statistical analysis

All safety analyses were performed on the intentionto-treat population. The objective response was assessed on the per-protocol population. The results are expressed as the mean±standard deviation or as ranges when appropriate. Follow-up started at the outset of treatment.

Results

1. Study population

A total of 23 patients received the investigational product. Baseline characteristics of patients are shown in Table 1. Median age was 56 years (range, 33 to 70 years). Thirteen patients (56.5 %) were male. Nine patients (39.1%) had ECOG PS 0, 13 patients (56.5%) had ECOG PS 1, and one patient had ECOG PS 2. The most common tumors were colorectal cancer (n=11) and lung cancer (n=3). Seventy-eight percent of patients had previously received more than three kinds of chemotherapies.

2. Dose escalation and DLTs

The investigational products were administered at doses of up 12 mg/m²/day. DLT was reported in two patients in the 12 mg cohort, which were grade 3 hypertension. One patient with DLT had hypertension, and the blood pressure was increased up to grade 3 at 1 hour (164/96 mm Hg) and 4 hours (155/95 mm Hg) after infusion of CKD-516. However, the blood pressure was normalized at 8 hours after infusion without any intervention. The other patient with DLT showed elevation of blood pressure up to grade 3 (175/95 mm Hg) at 4 hours after infusion of CKD-516 and received anti-hypertensive medication (nicardipine), which led to the normalization of blood pressure 8 hours after infusion. There was no abnormality in troponin I, CPK-MB, and ECG in both DLT cases. The MTD of CKD-516 was determined as 12 mg/m²/day.

3. Adverse events

A total of 58 cycles of CKD-516 were administered to the patients. Most commonly reported AEs during all treatment periods were gastrointestinal AE, that is, diarrhea (34.8%; 30.4% grade 1/2, 13.0% grade 3), nausea (21.7%, all grade 1/2), and vomiting (21.7%, all grade 1/2) (Table 2). Grade 1/2 anorexia and myalgia were 30.4% and 17.4%, respectively. Abdominal pain occurred in 21.7% (grade 1/2, 21.7%; grade 3, 4.3%). Grade 1/2 neutropenia and thrombocytopenia were reported as 4.3% and 4.3%. Anemia occurred in 8.7% (grade 1/2, 8.7%; grade 3, 4.3%). Hypertension was observed two patients (two DLT cases [grade 3, 8.7%], one patient [grade 2, 4.3%] ). One patient (4.3%) had grade 3 acute coronary syndrome.

4. Pharmacokinetic analysis

The plasma concentration-time profiles of CKD-516 and its metabolite S-516 showed a similar trend at all dosing levels (Table 3). C_max of CKD-516 were 45.88±15.04 μg/L (mean±standard deviation), 78.89±39.99 μg/L, 129.02±55.50 μg/L, 140.93±17.56 μg/L, 297.33±89.29 μg/L, 273.32±93.37 μg/L, and 646.75±513.71 μg/L at seven dosing levels, respectively. C_max of S-516 were 19.65±2.38 μg/L, 37.52±3.72 μg/L, 59.75±5.83 μg/L, 128.83±7.12 μg/L, 110.43±17.30 μg/L, 141.20±27.74 μg/L, and 222.75±3.04 μg/L at seven dosing levels, respectively (Fig. 1). CKD-516 underwent almost complete biotransformation to S-516 with only < 1% of unchanged CKD-516 excreted in the urine. A good linear relationship between dose and PK parameters indicated the linear pharmacokinetic characteristics of CKD-516 and S-516 over all dose levels (Fig. 2).

5. Antitumor activity

Response evaluation was possible in all 23 patients. None of the patients had CR or PR response. Six patients were assessed as SD (26.1%) and 17 patients showed progressive disease (73.9%). One patient showed 2.8% tumor reduction. Median progression-free survival was 39 days (95% confidence interval, 37 to 41 days). Three patients received the study treatment up to six cycles (1 osteosarcoma at 1 mg, 1 renal cell carcinoma at 3.3 mg, 1 colon cancer at 3.3 mg). The reasons for termination of treatment were disease progression (21 patients), no recovery of disease-related condition within 5 weeks (1 patient), and investigator’s discretion (1 patient).

Discussion

This was the phase I, first-in-human study of novel VDA, CKD-516, administered on D1 and D8 every 3 weeks in patients with advanced solid tumors. The result provides evidence of the tolerability of a VDA in patients with solid tumor. The MTD was defined as 12 mg/m²/day. The DLT was grade 3 hypertension. Up to the MTD, most common AEs were gastrointestinal AEs. The PK of CKD-516 and its metabolite (S-516) were demonstrated in this study, which showed the linear PK.

We had two DLT patients. One patient had colon cancer and previously received standard chemotherapies (XELOX, FOLFIRI, capecitabine). This patient had a history of hypertension without other cardiac disease and had received antihypertensive medication. The baseline blood pressure before infusion of CKD-516 was 125/82 mm Hg, and was increased up to grade 3 at 1 hour (164/96 mm Hg) and 4 hours (155/95 mm Hg) after infusion of CKD-516, and normalized at 8 hours without any intervention. The other patient had ampulla of Vater cancer with treatment history of gemcitabine, cisplatin, and 5-fluorouracil. The baseline blood pressure before infusion of CKD-516 was 119/77 mm Hg. After 1 hour of infusion, blood pressure was 111/75 mm Hg, and elevated up to grade 3 (175/95 mm Hg) at 4 hours and anti-hypertensive medication was administered, which led to the normalization of blood pressure at 8 hours.

The most commonly reported DLTs for other VDAs under development are cardiac-related events including hypertension, corrected QT (QTc) prolongation, myocardial ischemia, atrial fibrillation, acute chest pain, acute reversible coronary ischemia, hypotension, troponin elevation or motor neuropathy or tumor pain [10-15]. Other frequently reported AEs are diarrhea, nausea, vomiting, fatigue, and headache. Therefore, the findings in our study are consistent with those of other studies testing VDAs.

For the toxicity pattern, dose modification or cycle delay of subsequent treatment after the first cycle, a total of 58 cycles were delivered to all enrolled patients (10 cycles in 1.0 mg, 5 cycles in 2.0 mg, 16 cycles in 3.3 mg, 4 cycles in 5.0 mg, 6 cycles in 7.0 mg, 10 cycles in 9.0 mg, and 7 cycles in 12.0 mg). Only two patients who showed DLTs were treated with a reduced dose in subsequent cycles. No other patient required dose reduction or delay in the subsequent treatments. Toxicity pattern in subsequent cycles was similar to that of the DLT observation cycle. Gastrointestinal AEs (diarrhea, nausea, and anorexia) were most common followed by myalgia and arthralgia. Most were grade 1/2. During all subsequent treatment cycles, no further grade of hypertension was detected.

The vascular disrupting effect of CKD-516 was previously evaluated with intravoxel incoherent motion diffusionweighted magnetic resonance imaging (MRI) or dynamic contrast-enhanced ultrasonography in a rabbit VX2 liver tumor model [16,17]. In our study, to observe the vascular disrupting effect of CKD-516 by dynamic contrast-enhanced MRI (DCE-MRI), 13 patients were evaluated by DCE-MRIs taken at screening and 24 hours after the first infusion of CKD-516. A trend of decreased K^trans and initial area under the curve (iAUC) was observed [18]. The reason for checking DCE-MRI at 24 hours after infusion of CKD-561 was based on previous animal data. The half-life of S-561, the active metabolite of CKD-561, was 85.1 minutes in dog. In an in vivo absorption experiment, the half-life of CKD-516 was 8.05 hours in dog. We hypothesized that the change of blood flow will take place within at least 3 to 4 times of half-life, around 24 hours. Actually, the half-life of S-516 in our study ranged from 4-6 hours.

We checked 5-hydroxyindoleacetic acid (5-HIAA) plasma concentration at pretreatment, 4 hours and 8 hours of CKD-516 infusion to determine whether the action mechanism of CKD-516 is associated with serotonin release, which was reported in other VDAs [19]. The levels of 5-HIAA of all patients were normal and there was no significant change of 5-HIAA levels after infusion of CKD-516, therefore, we concluded that the action mechanism of CKD-516 was not associated with serotonin release.

In terms of antitumor efficacy, there was no CR/PR patient. Three patients received CKD-516 up to six cycles (1 osteosarcoma, 1 renal cell carcinoma, 1 colon cancer). In our study, we used RECIST ver. 1.1 for evaluation of efficacy in accordance with other previous studies of VDAs.

Based on limited data, selection of optimal tumor types for further development of VDAs is challenging. So far, there have been no biomarkers for prediction of the efficacy of VDAs. Based on the preclinical combination study of VDAs with cytotoxic chemotherapies, one of the future strategies for development of VDAs is combination with cytotoxic chemotherapy.

The half-life of CKD-516 in our study was relatively short. Now, a different dosing schedule of CKD-516 is under investigation (ClinicalTrials.gov identifier: NCT01560325). In this another phase I study, we are testing D1, D4, D8, and D11 infusion of CKD-516 out of a 21-day cycle. Using the result of this phase I study altogether, we will decide on the clinically recommended dose and schedule.

Conclusion

In conclusion, this study confirms the feasibility of a novel VDA, CKD-516, in patients with advanced solid tumor. CKD-516, at the MTD of 12 mg/m²/day, administered on D1 and D8 every 3 weeks, is safe and well tolerated.

NOTES

Conflict of interest relevant to this article was not reported.

Fig. 1.

Mean plasma concentration-time profiles of CKD-516 (A) and S-516 (B) after a single intravenous dose. The inserts show the profiles by log-linear scale. Bars represent standard deviations.

Fig. 2.

Regression analysis of maximum concentration (C_max) of CKD-516 (A) and S-516 (B) by dose. Solid lines are regression lines and dotted lines represent 95% confidence intervals.

Table 1.

Patient characteristics (n=23)

Characteristic	No. (%)
Median age (range, yr)	56 (33-70)
Sex
Male	13 (56.5)
Female	10 (43.5)
ECOG PS
0	9 (39.1)
1	13 (56.5)
2	1 (4.3)
Tumor
Colorectal cancer	11 (47.8)
Lung cancer	3 (13.0)
Ovary cancer	2 (8.7)
Cervix cancer	2 (8.7)
Renal cell cancer	2 (8.7)
Gastric cancer	1 (4.3)
Hepatocellular carcinoma	1 (4.3)
Esophageal cancer	1 (4.3)
Bone cancer	1 (4.3)
Cardiac cancer	1 (4.3)
Ampulla of Vater cancer	1 (4.3)
Thymic cancer	1 (4.3)
Previous chemotherapy
1	1 (4.3)
2	3 (13.0)
3	8 (34.8)
4	4 (17.4)
≥ 5	6 (26.1)

ECOG PS, Eastern Cooperative Oncology Group performance status.

Table 2.

All adverse events

Variable	Dosing level (mg/m²/day)
	1.0 (n=3)		2.0 (n=3)		3.3 (n=3)		5.0 (n=3)		7.0 (n=3)		9.0 (n=6)		12.0 (n=2)		Total (n=23)
	Gr 1/2	Gr 3/4	Gr 1/2	Gr 3/4	Gr 1/2	Gr 3/4	Gr 1/2	Gr 3/4	Gr 1/2	Gr 3/4	Gr 1/2	Gr 3/4	Gr 1/2	Gr 3/4	Gr 1/2	Gr 3/4
Diarrhea	2	0	1	0	1	1	1	0	0	0	0	1	2	1	7	3
Nausea	0	0	0	0	1	0	2	0	0	0	1	0	1	0	5	0
Vomiting	0	0	0	0	0	0	1	0	0	0	2	0	2	0	5	0
Dyspepsia	1	0	0	0	0	0	1	0	0	0	1	0	1	0	4	0
Anorexia	0	0	0	0	1	0	2	0	1	0	1	0	2	0	7	0
Abdominal pain	0	0	0	0	1	0	2	1	0	0	0	0	2	0	5	1
Fatigue	0	0	0	0	0	0	1	0	0	0	1	0	0	0	2	0
Peripheral sensory neuropathy	1	0	0	0	0	0	2	0	1	0	5	0	1	0	10	0
Myalgia	1	0	0	0	0	0	0	0	0	0	2	0	1	0	4	0
Arthralgia	1	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0
Dyspnea	0	0	1	0	1	0	2	0	0	0	0	0	0	0	4	0
Anemia	0	0	1	1	0	0	1	0	0	0	0	0	0	0	2	1
Neutropenia	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Thrombocytopenia	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0
Acute coronary syndrome	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1
Sinus tachycardia	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0
Hypertension	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	2

Gr, grade.

Table 3.

Pharmacokinetic parameters of plasma CKD-516 and its metabolite S-516 after a single intravenous infusion of CKD-516

Dose (mg/m²/day)	CKD-516							S-516
Dose (mg/m²/day)	t_max (hr)^a)	C_max (μg/L)	AUC_last (μg‧hr/L)	t_1/2 (hr)	V_z (L)	CL (L/hr)	fe	t_max (hr)^a)	C_max (μg/L)	AUC_last (µg‧hr/L)	t_1/2 (hr)
1.0 (n=3)	0.52	45.88±15.04	18.39±1.87	0.34±0.03	43.76±12.64	88.33±19.63	0.0043±0.0009	0.68	19.65±2.38	84.42±21.96	4.71±0.98
	(0.52-0.53)	(34.69-62.98)	(16.27-19.79)	(0.31-0.36)	(32.78-57.59)	(73.66-110.62)	(0.3100-0.3300)	(0.67-0.85)	(17.69-22.29)	(60.01-102.58)	(3.58-5.28)
2.0 (n=3)	0.50	78.89±39.99	37.24±8.33	0.59±0.07	80.09±27.45	92.69±20.78	0.0018±0.0002	0.65	37.52±3.72	139.93±46.74	4.64±0.39
	(0.25-0.50)	(42.03-121.40)	(27.85-43.76)	(0.54-0.67)	(57.47-110.63)	(74.09-115.11)	(0.0016-0.0020)	(0.62-0.67)	(34.59-41.71)	(102.71-192.39)	(4.19-4.89)
3.3 (n=3)	0.50	129.02±55.50	64.94±20.97	0.62±0.13	84.54±20.07	97.07±29.04	0.0045±0.0015	0.67	59.75±5.83	299.04±28.14	6.23±1.35
	(0.25-0.52)	(87.27-192.00)	(49.70-88.85)	(0.50-0.75)	(69.01-107.20)	(64.09-118.82)	(0.0028-0.0055)	(0.67-0.68)	(56.38-66.49)	(268.22-323.38)	(5.02-7.69)
5.0 (n=3)	0.50	140.93±17.56	67.15±9.15	0.57±0.04	103.12±13.80	126.04±21.07	0.0015±0.0013	0.68	128.83±7.12	511.65±36.60	4.62±0.58
	(0.50-0.75)	(130.20-161.20)	(56.83-74.26)	(0.54-0.61)	(93.16-118.88)	(105.27-147.39)	(0.0005-0.0030)	(0.65-0.70)	(121.40-135.60)	(469.82-537.77)	(3.96-5.07)
7.0 (n=3)	0.50	297.33±89.29	149.22±33.23	0.92±0.43	98.90±20.51	79.93±21.85	0.0009^b)	0.67	110.43±17.30	464.79±118.63	4.44±1.12
	(0.50-0.50)	(229.50-398.50)	(125.75-187.25)	(0.61-1.22)	(84.39-113.40)	(64.48-95.38)	(0.0009-0.0009)	(0.67-0.67)	(99.89-130.40)	(345.40-582.65)	(3.24-5.46)
9.0 (n=6)	0.50	273.32±93.37	145.76±37.27	0.91±0.26	140.66±44.06	108.11±28.06	0.0031±0.0029	0.67	141.20±27.74	726.66±205.91	4.54±1.04
	(0.25-0.52)	(170.40-441.00)	(91.73-201.49)	(0.65-1.41)	(90.77-187.11)	(75.12-142.93)	(0.0004-0.0084)	(0.50-0.68)	(114.60-185.50)	(538.03-1,088.24)	(3.94-6.63)
12.0 (n=2)	0.51	646.75±513.71	253.16±130.30	1.27±0.23	192.19±119.69	100.46±47.34	0.0022±0.0027	0.58	222.75±3.04	1,447.56±512.74	6.57±1.66
	(0.50-0.52)	(283.50-1,010.00)	(161.02-345.30)	(1.11-1.43)	(107.56-276.82)	(66.98-133.93)	(0.0003-0.0041)	(0.50-0.67)	(220.60-224.90)	(1,085.00-1,810.12)	(5.39-7.75)

Values are presented as mean±standard deviation (range). t_max, time to maximum concentration; C_max, maximum concentration; AUC_last, area under the curve up to measurable time-point; t_1/2, half-life; V_z, distribution volume at terminal phase; CL, clearance; fe, fraction excreted in urine.

^a) t_max is presented as the median,

^b) Only 1 subject was evaluated.

REFERENCES

1. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9:790–803. Article PubMed PMC
2. Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumorvascular disrupting agents. Cancer Treat Rev. 2011;37:63–74. Article PubMed PMC
3. Sessa C, Lorusso P, Tolcher A, Farace F, Lassau N, Delmonte A, et al. Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. Clin Cancer Res. 2013;19:4832–42. Article PubMed
4. Eskens FA, Tresca P, Tosi D, Van Doorn L, Fontaine H, Van der Gaast A, et al. A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours. Br J Cancer. 2014;110:2170–7. Article PubMed PMC
5. Li J, Jamin Y, Boult JK, Cummings C, Waterton JC, Ulloa J, et al. Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography. Br J Cancer. 2014;110:1727–32. Article PubMed PMC
6. Lee J, Kim SJ, Choi H, Kim YH, Lim IT, Yang HM, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem. 2010;53:6337–54. Article PubMed
7. Lee J, Bae S, Lee SH, Choi H, Kim YH, Kim SJ, et al. Discovery of a potent tubulin polymerization inhibitor: synthesis and evaluation of water-soluble prodrugs of benzophenone analog. Bioorg Med Chem Lett. 2010;20:6327–30. Article PubMed
8. Moon CH, Lee SJ, Lee HY, Dung le TK, Cho WJ, Cha H, et al. CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model. Invest New Drugs. 2014;32:400–11. Article PubMed
9. Kim YI, Kim KW, Lee HK, Park J, Chung JW, Youn H, et al. Enhanced efficacy of CKD-516 in combination with doxorubicin: pre-clinical evaluation using a hepatocellular carcinoma xenograft model. Anticancer Res. 2014;34:1715–22. PubMed
10. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol. 2003;21:2815–22. Article PubMed
11. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol. 2003;21:4428–38. Article PubMed
12. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002;62:3408–16. PubMed
13. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol. 2006;24:1491–8. Article PubMed
14. Mita MM, Spear MA, Yee LK, Mita AC, Heath EI, Papadopoulos KP, et al. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. Clin Cancer Res. 2010;16:5892–9. Article PubMed
15. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res. 2006;12:2834–40. Article PubMed
16. Joo I, Lee JM, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology. 2014;272:417–26. Article PubMed
17. Joo I, Kim JH, Lee JM, Choi JW, Han JK, Choi BI. Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in rabbit VX2 liver tumors. Ultrasonography. 2014;33:18–25. Article PubMed PMC PDF
18. Kim KW, Lee JM, Jeon YS, Kang SE, Baek JH, Han JK. Free-breathing dynamic contrast-enhanced MRI of the abdomen and chest using a radial gradient echo sequence with K-space weighted image contrast (KWIC). Eur Radiol. 2013;23:1352–60. Article PubMed
19. Baguley BC. Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer. Clin Lung Cancer. 2011;12:81–6. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors
Xiao-Li Wei, Hao-Xiang Wu, Dan-Yun Ruan, Feng Wang, Li Xu, Yu-Hong Li, Yu-Xiang Ma, Zhi-Qiang Wang, Yun-Peng Yang, Liang-Wei Tang, Bao-Lin Chen, Zhi-Quan Yong, Rui-Hua Xu, Hong-Yun Zhao
Cell Reports Medicine.2025; 6(2): 101969. CrossRef
Natural‐Product‐Inspired Discovery of Trimethoxyphenyl‐1,2,4‐triazolosulfonamides as Potent Tubulin Polymerization Inhibitors
Vajja Krishna Rao, Anvesh Ashtam, Dulal Panda, Sankar K. Guchhait
ChemMedChem.2024;[Epub] CrossRef
Thiazole, Isatin and Phthalimide Derivatives Tested in vivo against Cancer Models: A Literature Review of the Last Six Years
Aline Ferreira Pinto, Janine Siqueira Nunes, José Eduardo Severino Martins, Amanda Calazans Leal, Carla Cauanny Vieira Costa Silva, Anderson José Firmino Santos da Silva, Daiane Santiago da Cruz Olímpio, Elineide Tayse Noberto da Silva, Thiers Araújo Camp
Current Medicinal Chemistry.2024; 31(20): 2991. CrossRef
CKD-516 potentiates the anti-cancer activity of docetaxel against epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer
Soo Jin Kim, Kyunghyeon Lee, Jaewoo Park, Miso Park, U. Ji Kim, Se-mi Kim, Keun Ho Ryu, Keon Wook Kang
Toxicological Research.2023; 39(1): 61. CrossRef
Virulence-attenuated Salmonella engineered to secrete immunomodulators reduce tumour growth and increase survival in an autochthonous mouse model of breast cancer
Lance B. Augustin, Liming Milbauer, Sara E. Hastings, Arnold S. Leonard, Daniel A. Saltzman, Janet L. Schottel
Journal of Drug Targeting.2021; 29(4): 430. CrossRef
A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer
Hyehyun Jeong, Yong Sang Hong, Jeong Eun Kim, Hyeong-Seok Lim, Joong Bae Ahn, Sang Joon Shin, Young Suk Park, Seung Tae Kim, Sae-Won Han, Tae-You Kim, Tae Won Kim
Investigational New Drugs.2021; 39(5): 1335. CrossRef
Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents
M. Shaheer Malik, Saleh A. Ahmed, Ismail I. Althagafi, Mohammed Azam Ansari, Ahmed Kamal
RSC Medicinal Chemistry.2020; 11(3): 327. CrossRef
Tumor regression and potentiation of polymeric vascular disrupting therapy through reprogramming of a hypoxia microenvironment with temsirolimus
Haiyang Yu, Na Shen, Yanli Bao, Li Chen, Zhaohui Tang
Biomaterials Science.2020; 8(1): 325. CrossRef
Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors
Hark Kyun Kim, Jeong Won Kang, Young‐Whan Park, Jung Young Kim, Minchae Kim, Soo Jin Kim, Se‐mi Kim, Keun Ho Ryu, Seonghae Yoon, Yun Kim, Joo‐Youn Cho, Keun Seok Lee, Tak Yun, Kiwon Kim, Mi Hyang Kwak, Tae‐Sung Kim, Jinsoo Chung, Joong‐Won Park
Pharmacology Research & Perspectives.2020;[Epub] CrossRef
Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors
Mai F. Tolba
International Journal of Cancer.2020; 147(11): 2996. CrossRef
Discovery of tertiary amide derivatives incorporating benzothiazole moiety as anti-gastric cancer agents in vitro via inhibiting tubulin polymerization and activating the Hippo signaling pathway
Jian Song, Qiu-Lei Gao, Bo-Wen Wu, Ting Zhu, Xin-Xin Cui, Cheng-Jun Jin, Shu-Yu Wang, Sheng-Hui Wang, Dong-Jun Fu, Hong-Min Liu, Sai-Yang Zhang, Yan-Bing Zhang, Yong-Chun Li
European Journal of Medicinal Chemistry.2020; 203: 112618. CrossRef
Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma
Min-Young Kim, Jung-Young Shin, Jeong-Oh Kim, Kyoung-Hwa Son, Yeon Sil Kim, Chan Kwon Jung, Jin-Hyoung Kang
BMC Cancer.2020;[Epub] CrossRef
Discovery and optimization of 3,4,5-trimethoxyphenyl substituted triazolylthioacetamides as potent tubulin polymerization inhibitors
Fang Yang, Cai-Ping He, Peng-Cheng Diao, Kwon Ho Hong, Jin-Jun Rao, Pei-Liang Zhao
Bioorganic & Medicinal Chemistry Letters.2019; 29(1): 22. CrossRef
Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics
Jason H. Gill, Kimberly L. Rockley, Carol De Santis, Asma K. Mohamed
Pharmacology & Therapeutics.2019; 202: 18. CrossRef
Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment
Na Shen, Jing Wu, Chenguang Yang, Haiyang Yu, Shengcai Yang, Tete Li, Jingtao Chen, Zhaohui Tang, Xuesi Chen
Nano Letters.2019; 19(11): 8021. CrossRef
Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site
Ling Li, Sibo Jiang, Xiaoxun Li, Yao Liu, Jing Su, Jianjun Chen
European Journal of Medicinal Chemistry.2018; 151: 482. CrossRef
Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
Ryszard Smolarczyk, Tomasz Cichoń, Ewelina Pilny, Magdalena Jarosz-Biej, Aleksandra Poczkaj, Natalia Kułach, Stanisław Szala
Scientific Reports.2018;[Epub] CrossRef
Chemoembolization with Vascular Disrupting Agent CKD-516 Dissolved in Ethiodized Oil in Combination with Doxorubicin: A VX2 Tumor Model Study
In Joon Lee, Myungsu Lee, Soo Jin Kim, You Kyung Kim, Jong Yun Won, Jin Wook Chung
Journal of Vascular and Interventional Radiology.2018; 29(8): 1078. CrossRef
Enhanced efficacy of radiofrequency ablation for hepatocellular carcinoma using a novel vascular disrupting agent, CKD-516
Su Jung Ham, YoonSeok Choi, Seul-I Lee, Jinil Kim, Young Il Kim, Jin Wook Chung, Kyung Won Kim
Hepatology International.2017; 11(5): 446. CrossRef
Early investigational tubulin inhibitors as novel cancer therapeutics
Kunal Nepali, Ritu Ojha, Hsueh-Yun Lee, Jing-Ping Liou
Expert Opinion on Investigational Drugs.2016; 25(8): 917. CrossRef
Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth
María-Jesús Pérez-Pérez, Eva-María Priego, Oskía Bueno, Maria Solange Martins, María-Dolores Canela, Sandra Liekens
Journal of Medicinal Chemistry.2016; 59(19): 8685. CrossRef
Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis
Souvik Banerjee, Dong-Jin Hwang, Wei Li, Duane Miller
Molecules.2016; 21(11): 1468. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors

Cancer Res Treat. 2016;48(1):28-36. Published online February 23, 2015

DOI: https://doi.org/10.4143/crt.2014.258

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors

Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors

Fig. 1. Mean plasma concentration-time profiles of CKD-516 (A) and S-516 (B) after a single intravenous dose. The inserts show the profiles by log-linear scale. Bars represent standard deviations.

Fig. 2. Regression analysis of maximum concentration (Cmax) of CKD-516 (A) and S-516 (B) by dose. Solid lines are regression lines and dotted lines represent 95% confidence intervals.

Fig. 1.

Fig. 2.

Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors

Characteristic	No. (%)
Median age (range, yr)	56 (33-70)
Sex
Male	13 (56.5)
Female	10 (43.5)
ECOG PS
0	9 (39.1)
1	13 (56.5)
2	1 (4.3)
Tumor
Colorectal cancer	11 (47.8)
Lung cancer	3 (13.0)
Ovary cancer	2 (8.7)
Cervix cancer	2 (8.7)
Renal cell cancer	2 (8.7)
Gastric cancer	1 (4.3)
Hepatocellular carcinoma	1 (4.3)
Esophageal cancer	1 (4.3)
Bone cancer	1 (4.3)
Cardiac cancer	1 (4.3)
Ampulla of Vater cancer	1 (4.3)
Thymic cancer	1 (4.3)
Previous chemotherapy
1	1 (4.3)
2	3 (13.0)
3	8 (34.8)
4	4 (17.4)
≥ 5	6 (26.1)

Variable	Dosing level (mg/m²/day)
	1.0 (n=3)		2.0 (n=3)		3.3 (n=3)		5.0 (n=3)		7.0 (n=3)		9.0 (n=6)		12.0 (n=2)		Total (n=23)
	Gr 1/2	Gr 3/4	Gr 1/2	Gr 3/4	Gr 1/2	Gr 3/4	Gr 1/2	Gr 3/4	Gr 1/2	Gr 3/4	Gr 1/2	Gr 3/4	Gr 1/2	Gr 3/4	Gr 1/2	Gr 3/4
Diarrhea	2	0	1	0	1	1	1	0	0	0	0	1	2	1	7	3
Nausea	0	0	0	0	1	0	2	0	0	0	1	0	1	0	5	0
Vomiting	0	0	0	0	0	0	1	0	0	0	2	0	2	0	5	0
Dyspepsia	1	0	0	0	0	0	1	0	0	0	1	0	1	0	4	0
Anorexia	0	0	0	0	1	0	2	0	1	0	1	0	2	0	7	0
Abdominal pain	0	0	0	0	1	0	2	1	0	0	0	0	2	0	5	1
Fatigue	0	0	0	0	0	0	1	0	0	0	1	0	0	0	2	0
Peripheral sensory neuropathy	1	0	0	0	0	0	2	0	1	0	5	0	1	0	10	0
Myalgia	1	0	0	0	0	0	0	0	0	0	2	0	1	0	4	0
Arthralgia	1	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0
Dyspnea	0	0	1	0	1	0	2	0	0	0	0	0	0	0	4	0
Anemia	0	0	1	1	0	0	1	0	0	0	0	0	0	0	2	1
Neutropenia	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Thrombocytopenia	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0
Acute coronary syndrome	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1
Sinus tachycardia	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0
Hypertension	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	2

Dose (mg/m²/day)	CKD-516							S-516
Dose (mg/m²/day)	t_max (hr)^a)	C_max (μg/L)	AUC_last (μg‧hr/L)	t_1/2 (hr)	V_z (L)	CL (L/hr)	fe	t_max (hr)^a)	C_max (μg/L)	AUC_last (µg‧hr/L)	t_1/2 (hr)
1.0 (n=3)	0.52	45.88±15.04	18.39±1.87	0.34±0.03	43.76±12.64	88.33±19.63	0.0043±0.0009	0.68	19.65±2.38	84.42±21.96	4.71±0.98
	(0.52-0.53)	(34.69-62.98)	(16.27-19.79)	(0.31-0.36)	(32.78-57.59)	(73.66-110.62)	(0.3100-0.3300)	(0.67-0.85)	(17.69-22.29)	(60.01-102.58)	(3.58-5.28)
2.0 (n=3)	0.50	78.89±39.99	37.24±8.33	0.59±0.07	80.09±27.45	92.69±20.78	0.0018±0.0002	0.65	37.52±3.72	139.93±46.74	4.64±0.39
	(0.25-0.50)	(42.03-121.40)	(27.85-43.76)	(0.54-0.67)	(57.47-110.63)	(74.09-115.11)	(0.0016-0.0020)	(0.62-0.67)	(34.59-41.71)	(102.71-192.39)	(4.19-4.89)
3.3 (n=3)	0.50	129.02±55.50	64.94±20.97	0.62±0.13	84.54±20.07	97.07±29.04	0.0045±0.0015	0.67	59.75±5.83	299.04±28.14	6.23±1.35
	(0.25-0.52)	(87.27-192.00)	(49.70-88.85)	(0.50-0.75)	(69.01-107.20)	(64.09-118.82)	(0.0028-0.0055)	(0.67-0.68)	(56.38-66.49)	(268.22-323.38)	(5.02-7.69)
5.0 (n=3)	0.50	140.93±17.56	67.15±9.15	0.57±0.04	103.12±13.80	126.04±21.07	0.0015±0.0013	0.68	128.83±7.12	511.65±36.60	4.62±0.58
	(0.50-0.75)	(130.20-161.20)	(56.83-74.26)	(0.54-0.61)	(93.16-118.88)	(105.27-147.39)	(0.0005-0.0030)	(0.65-0.70)	(121.40-135.60)	(469.82-537.77)	(3.96-5.07)
7.0 (n=3)	0.50	297.33±89.29	149.22±33.23	0.92±0.43	98.90±20.51	79.93±21.85	0.0009^b)	0.67	110.43±17.30	464.79±118.63	4.44±1.12
	(0.50-0.50)	(229.50-398.50)	(125.75-187.25)	(0.61-1.22)	(84.39-113.40)	(64.48-95.38)	(0.0009-0.0009)	(0.67-0.67)	(99.89-130.40)	(345.40-582.65)	(3.24-5.46)
9.0 (n=6)	0.50	273.32±93.37	145.76±37.27	0.91±0.26	140.66±44.06	108.11±28.06	0.0031±0.0029	0.67	141.20±27.74	726.66±205.91	4.54±1.04
	(0.25-0.52)	(170.40-441.00)	(91.73-201.49)	(0.65-1.41)	(90.77-187.11)	(75.12-142.93)	(0.0004-0.0084)	(0.50-0.68)	(114.60-185.50)	(538.03-1,088.24)	(3.94-6.63)
12.0 (n=2)	0.51	646.75±513.71	253.16±130.30	1.27±0.23	192.19±119.69	100.46±47.34	0.0022±0.0027	0.58	222.75±3.04	1,447.56±512.74	6.57±1.66
	(0.50-0.52)	(283.50-1,010.00)	(161.02-345.30)	(1.11-1.43)	(107.56-276.82)	(66.98-133.93)	(0.0003-0.0041)	(0.50-0.67)	(220.60-224.90)	(1,085.00-1,810.12)	(5.39-7.75)

Table 1. Patient characteristics (n=23)

ECOG PS, Eastern Cooperative Oncology Group performance status.

Table 2. All adverse events

Gr, grade.

Table 3. Pharmacokinetic parameters of plasma CKD-516 and its metabolite S-516 after a single intravenous infusion of CKD-516